Evolution of insulin patents and market exclusivities in the USA

The Lancet Diabetes and Endocrinology

Volumn 3, Issue 11, 2015, Pages 835-837

  Luo, Jing ^a   Kesselheim, Aaron S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; INSULIN; INSULIN GLARGINE; ANTIDIABETIC AGENT;

DIABETES MELLITUS; DRUG COST; DRUG MANUFACTURE; DRUG MARKETING; EUROPE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE NEED; HUMAN; MEDICAID; NOTE; PATENT; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES; DRUG DESIGN; ECONOMICS;

DIABETES MELLITUS; DRUG DESIGN; DRUGS, GENERIC; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PATENTS AS TOPIC; UNITED STATES;

EID: 84944931374     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(15)00364-2     Document Type: Note

References (12)

1. IDF Diabetes Atlas 2014, International Diabetes Federation, International Diabetes Federation, Brussels. 6th edn.
2. Zhuo X, Zhang P, Kahn HS, Bardenheier BH, Li R, Gregg EW Change in medical spending attributable to diabetes: national data from 1987 to 2011. Diabetes Care 2015, 38:581-587.
3. Lipska KJ, Ross JS, Van Houten HK, Beran D, Yudkin JS, Shah ND Use and out-of-pocket costs of insulin for type 2 diabetes mellitus from 2000 through 2010. JAMA 2014, 311:2331-2333.
4. Luo J, Avorn J, Kesselheim AS Trends in Medicaid reimbursements for insulin from 1991 through 2014. JAMA Intern Med 2015, published online Aug 24. 10.1001/jamainternmed.2015.4338.
5. Sanofi's next-generation insulin shows edge over Lantus Reuters, (accessed Aug 6, 2015). http://uk.reuters.com/article/2013/06/22/us-sanofi-lantus-idUSBRE95L08R20130622.
6. Greene JA, Riggs KR Why is there no generic insulin? Historical origins of a modern problem. N Engl J Med 2015, 372:1171.
7. Frank RG, Salkever DS Generic entry and the pricing of pharmaceuticals. J Econ Manag Strat 1997, 6:75-90.
8. Keith K, Nicholson D, Rogers D Accuracy and precision of low-dose insulin administration using syringes, pen injectors, and a pump. Clin Pediatr (Phila) 2004, 43:69-74.
9. Heinemann L Biosimilar insulins. Expert Opin Biol Ther 2012, 12:1009-1016.
10. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues 2015, European Medicines Agency, European Medicines Agency, London.
11. Price WN, Rai AK Are trade secrets delaying biosimilars?. Science 2015, 348:188-189.
12. Engelberg AB, Kesselheim AS, Avorn J Balancing innovation, access, and profits-market exclusivity for biologics. N Engl J Med 2009, 361:1917-1919.